© 2021 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
The kinase inhibitor delayed disease progression by 27% for people who had tried at least two prior therapies.
Researchers have identified another molecule that may lead to the development of more effective targeted medications.
The theme of this issue is the science underlying advances in cancer care and treatment.
More than 80% of lung cancer patients treated with the targeted therapy experienced remission or had stable disease.
Opdivo plus Cabometyx reduced the risk of death by 40%.
The targeted therapy delayed disease progression in people with advance non-small-cell lung cancer, including those with brain metastasis.
First-line Lenvima plus Keytruda yields better overall survival for patients with metastatic kidney cancer.
Umbralisib led to remission in 49% of patients with marginal zone lymphoma and 43% of those with follicular lymphoma.
The new targeted therapy was approved for non-small-cell lung cancer with a specific MET mutation.
The immunotherapy combination slowed disease progression and reduced the risk of death by 40%.
Dana-Farber Cancer Institute discusses what it means to be in remission and the transition into survivorship.
Treatment with Tecentriq plus Avastin or with Keytruda alone delays disease progression and improves survival.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
